Trial:
A multi-center, open label study assessing the efficacy of Erenumab on functional impact of migraine
Purpose:
To see what effect Erenumab has on health and lifestyle, beyond the effect on the number of migraine days each month
Key Criteria:
▪ adults (18-65) with migraines 4 – 20 per month only
▪ migraines have at least a moderate impact on function
▪consistent migraine presentation in intensity and frequency for the last 90 days
▪ no CGRP medication in the last 6 months (prevention or rescue)
▪ no changes to prevention medication doses for the last 90 days
▪ no trigger point or nerve block injections for the last 2 months
▪ open to starting aimovig 140mg monthly X 3 doses
Join the Study
If you fit the key criteria and are interested in joining the study please email us at research@thediamondheadache.com
